Starpharma Holdings Limited (ASX:SPL – Get Free Report) insider Robert Thomas acquired 100,000 shares of the stock in a transaction dated Monday, April 15th. The stock was acquired at an average cost of A$0.13 ($0.08) per share, with a total value of A$13,000.00 ($8,387.10).
Robert Thomas also recently made the following trade(s):
- On Wednesday, April 10th, Robert Thomas acquired 250,000 shares of Starpharma stock. The stock was acquired at an average cost of A$0.17 ($0.11) per share, with a total value of A$43,500.00 ($28,064.52).
Starpharma Stock Performance
The company has a quick ratio of 5.65, a current ratio of 5.60 and a debt-to-equity ratio of 9.08.
About Starpharma
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.
Read More
- Five stocks we like better than Starpharma
- How to Use High Beta Stocks to Maximize Your Investing Profits
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Warren Buffett Stocks to Buy Now
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
- ETF Screener: Uses and Step-by-Step Guide
- Abbott Laboratories Outlook is Healthy: Buy the Dip
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
